scout
|Articles|December 1, 2006

Oncology NEWS International

  • Oncology NEWS International Vol 15 No 12
  • Volume 15
  • Issue 12

Pharmion Purchases Cabrellis, US Developer of Amrubicin

Pharmion Corporation has acquired Cabrellis Pharmaceuticals and gained US and European rights to amrubicin, a third-generation synthetic anthracycline currently in phase II trials for small-cell lung cancer in North America and Europe.

BOULDER, Colorado—Pharmion Corporation has acquired Cabrellis Pharmaceuticals and gained US and European rights to amrubicin, a third-generation synthetic anthracycline currently in phase II trials for small-cell lung cancer in North America and Europe.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.


Latest CME